Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®

This trial will provide a proof of concept that a dose range of Menomune given ID can induce an immune response that is comparable to standard dosing by the SC route, and is equivalent or superior to a low dose given SC.

Subjects will be randomized according to a computer-generated randomization schedule to receive the vaccine by SC injection or by ID injection at different dosages.

Inclusion criteria

• 18 to 55 years of age.
• Willing to return for 3 follow-up visits and comply with a 30 day follow-up period.
• Signed an informed consent form.

Exclusion criteria

• Allergy to any component of the vaccine and latex.
• Known or suspected immunodeficiency or receipt of immunosuppressive therapy or blood products within the previous two months.
• History of serious chronic diseases (such as cardiac or renal disease).
• Acute febrile illness at the time of visit.
• Pregnancy.
• Receipt of any vaccine within the 28 days prior to enrollment.
• Receipt of meningococcal vaccine (example in Military) within the past 5 years or history of meningococcal disease.